Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + lenvatinib + chemotherapy versus standard of care for first-line metastatic esophageal squamous cell carcinoma
2020-001911-26Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Pembrolizumab + lenvatinib + chemotherapy with Standard of care (2 arms). Primary endpoint: Number of participants with dose-limiting toxicities. Started Apr 2021; status: active.
02
Drugs
pembrolizumablenvatinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2020-001911-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001911-26.